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Sporadic amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, most likely results
from complex genetic and environmental interactions. Although a number of association studies have been
performed in an effort to find genetic components of sporadic ALS, most of them resulted in inconsistent
findings due to a small number of genes investigated in relatively small sample sizes, while the replication of
results was rarely attempted. Defects in retrograde axonal transport, vesicle trafficking and xenobiotic meta-
bolism have been implicated in neurodegeneration and motor neuron death both in human disease and animal
models.To assess the role of common genetic variation in these pathways in susceptibility to sporadic ALS, we
performed a pathway-based candidate gene case-control association study with replication. Furthermore,
we determined reliability of whole genome amplified DNA in a large-scale association study. In the first stage
of the study, 1277 putative functional and tagging SNPs in 134 genes spanning 8.7Mb were genotyped in 822
British sporadic ALS patients and 872 controls using whole genome amplified DNA. To detect variants with
modest effect size and discriminate among false positive findings 19 SNPs showing a trend of association in the
initial screen were genotyped in a replication sample of 580 German sporadic ALS patients and 361 controls.
We did not detect strong evidence of association with any of the genes investigated in the discovery sample
(lowest uncorrected P-value 0.00037, lowest permutation corrected P-value 0.353). None of the suggestive asso-
ciations was replicated in a second sample, further excluding variants with moderate effect size.We conclude
that common variation in the investigated pathways is unlikely to have a major effect on susceptibility to spora-
dic ALS.The genotyping efficiency was only slightly decreased (»1%) and genotyping quality was not affected
using whole genome amplified DNA. It is reliable for large scale genotyping studies of diseases such as ALS,
where DNA sample collections are limited because of low disease prevalence and short survival time.
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Amyotrophic lateral sclerosis (ALS) is a devastating neuro-
degenerative disease characterized by progressive muscle
weakness and wasting with combined upper and lower
motor neuron loss. It is the most common motor neuron
disease in the developed world with a lifetime risk of 1 : 600 to
1 : 1000 (Pasinelli and Brown, 2006). About 10% of ALS cases
are familial mostly with autosomal dominant inheritance
(Pasinelli and Brown, 2006); the remaining cases, often
referred to as sporadic, most likely result from complex
genetic and environmental interactions. Mutations in the
superoxide dismutase 1 (SOD1) gene are identified in up to
20% of familial (Rosen, 1993) and in 3–7% of sporadic ALS
patients (Jones et al., 1994, 1995; Jackson et al., 1997) and are
the most frequent known cause of ALS. A few other genes, for
example senataxin (SETX) (Chance et al., 1998; Chen et al.,
2004), VAMP (vesicle-associated membrane protein)-
associated protein B (VAPB) (Nishimura et al., 2004), and
alsin (ALS2) (Yang et al., 2001; Hadano et al., 2001), have
been shown to be mutated in rare forms of familial ALS and
other forms of motor neuron degeneration (Pasinelli and
Brown, 2006; James and Talbot, 2006); however, the aetiology
of more than 98% of ALS cases remains unclear. Given
that most of our understanding of disease pathogenesis at a
molecular level comes from research on SOD1-related
ALS, which comprises only 2% of all cases, it is crucial to
identify other disease risk factors, both genetic and
environmental.
To date, no genetic risk factors have been unequivocally
shown to be associated with sporadic ALS, the best
replicated findings so far being regulatory polymorphisms
in vascular endothelial growth factor (VEGF) (Lambrechts
et al., 2003), copy number variation at the Survival Motor
Neuron (SMN) locus (Corcia et al., 2002, 2006; Veldink
et al., 2005) and differences in tail lengths in the heavy
chain neurofilament gene (NEFH) (Al-Chalabi et al., 1999).
One reason for this lack of associations is highlighted by
Simpson and Al-Chalabi (2006) in that most of the
previous genetic studies of sporadic ALS have been limited
to assessing a small number of genes within patient and
control groups of relatively small sample sizes—generally a
few hundred patients and controls—resulting in incon-
sistent findings. For the same reason, replications of
association are only very rarely reported or attempted.
Until recently, the difficulties in carrying out such studies
have been the lack of availability of human genome
variation data and the available platforms for high
throughput analysis of genetic variation. Within the last
2 years, new data on common human genetic variation
have been published by the International HapMap project
(Altshuler et al., 2005) and new and more reliable and
robust genotyping platforms have become available, both of
which greatly enhance our ability to carry out large-scale
association studies. The HapMap project has facilitated high
throughput analysis of human variation by providing the
correlational structure of single nucleotide polymorphisms
(SNPs) which enables us to select small set of tagging
SNPs for genotyping to capture the most common variants
in large portions of the human genome (de Bakker
et al., 2005).
Given these new developments, we set out to undertake
an integrated genetic association study in ALS, for the first
time focusing on specific pathways/protein complexes
of interest, as determined by published data implicating
members of the pathway in ALS specifically or in other
related forms of neurodegeneration. The three pathways/
protein complexes we studied were those involved in
(i) axonal transport, specifically retrograde axonal trans-
port, (ii) vesicle trafficking and (iii) xenobiotic metabolism.
Axonal retrograde transport: This form of axonal
transport is driven by cytoplasmic dynein, a multi-subunit
motor complex moving towards the minus end of
microtubules. Cytoplasmic dynein interacts with dynactin,
which acts as a cargo adaptor and affects motor processivity
(Pfister et al., 2006; Duncan and Goldstein, 2006). Defects
in axonal transport have been implicated in motor neuron
degeneration both in human disease and in mouse models.
Transgenic mice overexpressing human mutant SOD1 that
model ALS have been shown to have slower retrograde
axonal transport (Murakami et al., 2001; Kieran et al.,
2005) and mutant SOD1 is known to disrupt dynein
localization (Murakami et al., 2001; Ligon et al., 2005).
Mutations in the cytoplasmic dynein 1 heavy chain 1
(Dync1h1) gene in mice result in slower retrograde axonal
transport and death of motor neurons (Hafezparast et al.,
2003), while interactions of the same mutant Dync1h1
alleles with mutant SOD1 increase lifespan of ALS mice,
and these double mutant mice have been shown to have
increased rates of retrograde axonal transport (Kieran et al.,
2005). A mutation in the dynactin p150 subunit was
identified in a family with a slowly progressive lower motor
neuron syndrome (Puls et al., 2003, 2005) and other
possible mutations have been identified in ALS patients
(Munch et al., 2004), while overexpression of dynamitin,
another subunit of dynactin, in mice causes disruption
of the dynein–dynactin complex and late onset motor
neuron disease (LaMonte et al., 2002). Thus disruption of
retrograde axonal transport is implicated in specific
degeneration of motor neurons, and in some kind of
interaction with mutant SOD1.
Vesicle trafficking: Defects in vesicular trafficking are
known to lead to death of motor neurons. The wobbler
mouse model for example has a mutation in the vesicular
sorting protein Vps54 (Schmitt-John et al., 2005), while
a mutation in CHMP2B, a component of the endosomal
secretory complex required for transport (ESCRTIII), may
result in frontotemporal dementia in a human pedigree
(Skibinski et al., 2005), a disease with considerable overlap
with ALS; two possible mutations in CHMP2B have been
identified in individuals with ALS (Parkinson et al., 2006).
Xenobiotic metabolism: Epidemiological studies have
shown association of ALS with exposure to environmental
toxins, pesticides and heavy-metals (reviewed in Nelson and
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McGuire, 2006), although the results of many published
studies are inconclusive. The exposure to such agents is
modulated by the xenobiotic metabolizing enzymes of an
individual, and enzyme activity is in part determined by
genetic variation in the genes encoding these enzymes.
Therefore we hypothesize that susceptibility to ALS could
be influenced by genetic variation in genes in the xenobiotic
metabolism pathways.
In summary, here we elucidate the role of common
genetic variation in retrograde axonal transport, vesicle
trafficking and major xenobiotic metabolism genes in
susceptibility to sporadic ALS in the most powerful
association study of ALS so far. We are specifically studying
individual pathways in this investigation. We comprehen-
sively screen variation in 134 genes in the largest collection
of sporadic ALS patients genotyped in a single study to date
and validate the results of association analysis by genotyp-
ing SNPs showing a trend of association in a replication
sample of ALS patients from Germany.
In addition, by performing the initial screen entirely on
whole genome amplified DNA we validate its use on a large
scale. The reduction in the amount of DNA required for
genotyping may significantly ameliorate the use of existing
old DNA collections and enhance collaborations studying
late onset neurodegenerative diseases where sample collec-
tions are limited because of low disease prevalence and
short survival time. The use of whole genome amplified
DNA until now has been limited to supplementing the
studies performed on genomic DNA with small numbers of
samples for which not enough DNA was available, and to
the best of our knowledge this is the largest genome screen
performed on whole genome amplified DNA.
Subjects and methods
Study plan and subjects
We used a two-stage study design with existing collections of
sporadic ALS cases and controls from two populations. In the
first, or discovery sample, we genotyped 822 British sporadic ALS
patients and 872 control DNA samples collected at out-patient
clinics at the Motor Neurone Disease Care and Research Centre,
Queen Elizabeth Hospital, Birmingham, UK (167 definite or
probable ALS patients according to El Escorial World Federation
criteria with unknown SOD1 mutation status and 145 controls),
King’s Motor Nerve Clinic, London, UK (258 definite or probable
ALS patients according to El Escorial criteria with no SOD1
mutations and 245 controls), the Newcastle and Sheffield MND
Centres, UK (84 ALS patients neuropathologically confirmed at
autopsy, 280 definite or probable ALS patients according to
El Escorial criteria, 33 patients with clinical variants of ALS
including primary lateral sclerosis and progressive muscular
atrophy with unknown SOD1 mutation status and 313 controls)
and National Blood Transfusion Service, UK (169 controls).
The second, or replication sample, consisted of 580 German
sporadic definite or probable ALS patients according to El Escorial
criteria with unknown SOD1 mutation status, collected at the
Motor Neuron Research Clinic, Wuerzburg, Germany and 361
controls, collected at the Department of Transfusion Medicine and
Immunohematology, University of Wuerzburg, Germany. None of
the patients had a known family history of ALS. The sample
characteristics are given in Table 1. DNA samples were extracted
from blood using standard methods. Participants of the study
signed informed consent and the study was approved by the
National Hospital for Neurology and Neurosurgery and Institute
of Neurology Joint Research Ethics Committee.
A set of SNPs covering most of the common variants in
candidate gene regions was genotyped in the discovery sample and
statistical analysis performed to look for evidence for association
with susceptibility to ALS. To detect modest effect size variants
and to discriminate among false positive findings, a subset of
SNPs that showed a trend for association in the discovery sample
was genotyped in the replication sample.
Candidate gene and SNP selection
The candidate genes were selected following a detailed review of
the literature on ALS-linked pathways and our experimental data
(DK, GS and EMCF, unpublished data). We included genes
encoding all known subunits of the dynein–dynactin complex,
genes regulating its activity, binding to cargoes, microtubules and
other interacting proteins; all known subunits of ESCRT
complexes known to be involved in vesicle trafficking; key
enzymes involved in pesticide metabolism and their targets. The
complete gene list is shown in Supplementary Table 1. The total
size of genome sequence investigated was 8.7Mb.
SNPs were selected in candidate gene regions based on positions
of RefSeq genes in the UCSC genome browser server
(http://genome.ucsc.edu) hg16 assembly, adding 10 000 bp to the
most 50- and 30-extent of the gene. As direct typing of causal
variants is more powerful in association studies, we enriched the
set of markers selected to genotype with the SNPs with predicted
functionality. First, selected regions were screened for SNPs with
predicted functionality using TAMAL software (Hemminger et al.,
2006). The SNPs were prioritized for genotyping if they had
frequency data in any major databases (dbSNP, HapMap, Perlegen
and Affymetrix) and met one of the following criteria: were in
coding regions, altered intronic splice sites, were in predicted
promoters, in regions with predicted regulatory potential, in
predicted transcription factor binding sites, in regions with
conservation scores 599th percentile genome-wide for human-
chimp-rat-mouse-chicken alignment or in miRNAs and their
30UTR targets. Functional SNPs for cytochrome P450 genes
were selected from the CYP450 database (http://www.imm.ki.se/
CYPalleles/). Secondly, tagging SNPs were selected based on
HapMap PhaseII data (release 19) using Tagger software
Table 1 Characteristics of genotyped ALS patient and
control samples
British German
ALS patients 822 579
Sex (males/females) 500/322 348/231
Type of onset
(limb/bulbar/mixed or undetermined)
513/234/75 444/132/3
Mean age of onset (range) 59 (20^87) 58 (16^85)
Controls 872 361
Sex (males/females/unknown) 430/442/0 190/136/35
Mean age at sample collection (range) 52 (17^81) 32 (18^65)
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(de Bakker et al., 2005). Since the majority of ALS patients were of
‘white’ ethnicity, only data on the HapMap CEU population were
used in selection of tagging SNPs. Where possible, putative
functional SNPs were used as tagging SNPs, and SNPs with higher
predicted genotyping scores from Illumina were prioritized in
selection—only SNPs with Illumina genotype scores 40.6 were
included in the assay. In total, 1279 tagging SNPs were selected to
capture variation of polymorphisms with minor allele frequencies
45% in the HapMap CEU population with mean maximum
pairwise r2 between tagging SNP and ungenotyped SNP of 0.90.
Eighty-three percent of all alleles with minor allele frequency of
40.05 were captured with r240.8 and 95.3% with r240.5. 157
SNPs not genotyped in the HapMap project were included
because of predicted functionality. One hundred neutral SNPs
were selected to control for population stratification. They were
selected to have minor allele frequencies of45% in the HapMap
CEU population and to be in more than 50 kb distance from any
RefSeq gene, known gene or RNA gene in UCSC genome hg17
assembly and not to be in the regions with predicted functionality
(as earlier).
Genotyping and quality control in the discovery
sample
British ALS patient and control samples were genotyped by 1536-
plex GoldenGate assay on an Illumina BeadArray station using
whole genome amplified DNA. Whole genome amplification was
performed using a Qiagen Repli-g Midi kit according to
manufacturer’s instructions using 100 ng of input genomic DNA
per reaction. The yields of amplified DNA were quantified using a
Picogreen assay (Molecular Probes, Inc) and concentrations
adjusted to 100 ng/ml. The sex of the samples was verified using
the amelogenin locus as a marker. We found 2% sex mismatches
and by typing additional sex-linked markers all of them were
confirmed to be errors in labelling the original genomic DNA
samples, therefore these samples were excluded from the study.
Three percent of whole genome amplified samples failed in PCRs
during sex testing and were removed from further study.
Genotyping quality control was ensured by (i) mixing case and
control samples on the same plates and genotyping blind to the
affection status; (ii) each plate contained five duplicate samples,
including one genomic DNA duplicate; (iii) three whole genome
amplified DNA samples from the Centre d’Etude du
Polymorphisme Humaine (CEPH) were genotyped and results
compared with HapMap data; (iv) SNPs that failed in more than
1% of the samples were removed to avoid non-random missing
data; and (v) SNPs showing departures from Hardy–Weinberg
equilibrium in controls were re-evaluated after analysis to check
for possible genotyping errors and differences in genotyping
performance between patient and control samples, such as
separate clustering of patient and control samples and differences
in intensity values.
Statistical analysis
The association was assessed by comparing genotype and allele
frequencies between affected and unaffected individuals. For the
genotypic test, a contingency table was made up for each SNP
consisting of the three genotype categories on one axis and the
phenotype categories on the other axis. The table was then
analysed using an extension of Fisher’s Exact Test to RC tables,
using a network algorithm developed by Mehta and Patel (1986)
and implemented using R software. To assess family-wise
significance of P-values, permutation analysis was performed
using routines written in R. False discovery rate analyses were
performed using the Benjamini and Hochberg linear step-up
procedure (Benjamini and Hochberg, 1995). We assumed the
proportion of true null hypotheses was close to 1, and that tests
were positive regression dependent (Benjamini and Yekutieli,
2001). The effect of hidden population substructure on association
statistics was assessed using the GCF Genomic Control method of
Devlin et al. (2004). Tests of sets of P-values against their uniform
expectation under the null, assuming independence of tests, were
performed using Fisher’s method for combining P-values.
Replication analysis
Permutations were performed to assess the significance of the
association results in the discovery sample and prioritize SNPs for
replication. In addition, all SNPs with uncorrected P-values below
0.01 in the genotypic test in the discovery sample were genotyped
in the replication sample, excluding SNPs in high linkage
disequilibrium with each other and SNPs from the genomic
control set. We also genotyped SNPs with P-values between 0.01
and 0.05 if they had a strong prediction of functionality according
to the following criteria: were in coding regions, within 6 bp from
exon–intron boundaries in fastDB database (de la Grange et al.,
2005), in 3’UTRs or experimentally proven promoters.
Blinded genotyping was performed using Taqman on a 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA)
using genomic DNA. As a quality control measure duplicates
(100% agreement) and water blanks were used. Association
statistics were calculated as earlier.
Results
Genotyping of whole genome amplified DNA
In total 1831 samples (95.4%) were genotyped successfully
on the Illumina BeadArray system, including 75 whole
genome amplified DNA blind duplicates and 17 genomic
DNA—whole genome amplified DNA blind duplicates.
1372 SNPs (89%) passed quality control criteria for
genotyping. We did not observe any differences between
genomic DNA and whole genome amplified sample
duplicates in genotyping performance.
In total 2 510 789 usable genotypes were produced
including 126 141 blind duplicates, of which 23 311 were
genomic DNA—whole genome amplified DNA duplicates.
Two mismatched duplicated genotypes were detected, both
of them in the same whole genome amplified duplicate
sample, indicating overall error rate 1.59 105. This also
suggests that errors are sample specific, but not likely
related to locus amplification bias during whole genome
amplification, as these duplicate samples were the products
of the same reaction. All genomic DNA—whole genome
amplified DNA duplicate genotypes matched exactly.
Genotypes of three whole genome amplified CEPH samples
were compared to genotypes from the HapMap project data
and one mismatch in 3706 compared genotypes was found,
which indicates an error rate of 0.00027.
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Marker coverage
1372 SNPs were genotyped successfully, including:
(1) 1156 (90% of attempted) tagging SNPs in 134
candidate gene regions, which captured the variation
of 5283 SNPs with minor allele frequencies of greater
than 5% in the HapMap CEU sample with a mean
maximum r2 0.865. 76.4% of alleles were captured
with r240.8 and 92.3% with r240.5. 301 of the
tagging SNPs had predicted functionality.
(2) 121 (77% of attempted) putative functional SNPs.
These SNPs were genotyped because of predicted
functionality, but either had minor allele frequency
55%, therefore could not be used as tagging SNPs,
or had not been genotyped in the HapMap
project therefore there was no prior information
of their tagging properties. Twenty of these SNPs
were monomorphic in our sample. We observed
the largest dropout in this set, despite the fact
that all these SNPs were validated by frequency in
at least one database (HapMap, dbSNP, Perlegen or
Affymetrix).
(3) Ninety-five (95% of attempted) SNPs from genomic
control set. All these SNPs had experimentally
validated Illumina assays (scores 1.1), therefore the
genotyping performance, as expected, was the best.
Hardy^Weinberg equilibrium and population
substructure
We examined the distribution of Hardy–Weinberg equilib-
rium P-values against the null expectation under both
Hardy–Weinberg equilibrium and linkage equilibrium. The
distribution of Hardy–Weinberg equilibrium P-values
showed a significant difference from uniform distribution
in controls (P¼ 0.03), but not in patients (P¼ 0.13).
However, after careful investigation we did not detect any
differences in genotyping quality between patient and
control samples, and therefore we believe the excess of
deviations from Hardy–Weinberg equilibrium may indicate
population substructure in the control sample rather than
errors in genotyping. We note that the two SNPs with the
lowest P-values in deviation from Hardy–Weinberg equilib-
rium were in the same gene (TRA1) and in linkage
disequilibrium (D’¼ 1), suggesting this is a real feature of
this locus. If these two SNPs are removed, the P-value
distribution is no longer significantly different from
uniform (P¼ 0.16). Modest population substructure was
also suggested by a marginal excess of low P-values in
association statistics in the genomic control set, where the
mean chi-square statistic over all loci differed significantly
from null expectation (P¼ 0.04). Hidden population
substructure may be the cause of false positive results if
disease frequency is different between subpopulations as
well as mask real associations. One method to deal with the
former is Genomic Control (Devlin et al., 2004), which
provides a simple correction to the single-marker chi-
square statistic for association that is applied uniformly
across all SNPs. None of the SNPs tested achieved formal
significance, even before genomic control correction
(see later), and the ranked order of P-values, used for
nominating SNPs for replication analysis, is unaffected by
genomic control correction (Supplementary Table 2).
Association analysis in the discovery sample
We ranked SNPs according to their genotypic P-values
for association. There were 17 SNPs with an uncorrected
P-value of 50.01 for the genotypic test (Tables 2 and 3,
Supplementary Table 2). We investigated the significance of
these findings using both Family-Wise Error Rate (FWER)
and False Discovery Rate (FDR) methods (Table 2 and
Supplementary Table 2). To account for dependency among
tests due to linkage disequilibrium, we used permutations
to estimate multiplicity-adjusted (family-wise) P-values.
None of the P-values reached significance after 1000
permutations, the lowest family-wise adjusted P-value
being 0.353 (rs7961369 in BICD1). We also calculated
multiplicity-adjusted q-values, defined as the minimum
FDR required to admit the kth ranked SNP into the pool
of declared hits. The minimum expected FDR required
to admit even one SNP under this method was 0.284.
Together, these results do not provide significant
support for association between the analysed SNPs and
susceptibility to ALS, over the alternative hypothesis of no
associated SNPs.
We repeated the analysis excluding the 33 samples from
patients with the primary muscular atrophy and primary
lateral sclerosis clinical subtypes of ALS and who did not
therefore strictly meet the El Escorial criteria for probable
or definite ALS. These subtypes were included in the initial
analysis because of the strong clinical suspicion that they
are part of the same disease process as classical ALS. The
results of both analyses highly correlated with r2 of 0.97.
Importantly, the 20 SNPs with lowest P-values, including all
SNPs with P50.01 were the same in both analyses. Primary
muscular atrophy and primary lateral sclerosis may be
considered to be the same pathological process as ALS,
therefore we chose to use the results of analysis of the full
dataset for SNP selection for replication.
Association analysis in the replication sample
Even though we did not detect unequivocal evidence of a
significant association in the initial screen, a Q–Q plot of
log observed P-values against expected indicated some
excess of SNPs with low P-values in our dataset. It could be
indicative of the presence of alleles with weak and moderate
effect size which our study was underpowered to detect,
even though the difference did not reach formal significance
(P¼ 0.12). To discriminate between false positives and
alleles with moderate effect size, we genotyped 19 SNPs in a
replication sample of 580 German sporadic ALS patients
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Table 2 Characteristics of SNPs genotyped in discovery and replication samples and association statistics, ranked according to P-values in the discovery (British)
sample.
SNP ID Gene Location
in gene
Function Genotype
counts
in British
patients
Genotype
counts
in British
controls
Unadjusted
P-value in
British
FDR
q-value
in British
HWE
P-value
in
British
controls
Genotype
counts
in German
patients
Genotype
counts
in
German
controls
Unadjusted
P-value
in
Germans
HWE
P-value in
German
controls
Joint
P-value
rs7961369 BICD1 Intron None 175/387/
260
196/474/
202
0.00037 0.284 0.010 144/259/165 82/162/103 0.84 0.242 0.0031
rs17488186 CAPZA3 Upstream Promoter
(predicted)
0/11/811 0/35/837 0.00081 0.301 0.545 0/17/564 0/10/351 1 0.790 0.012
rs17191358 ANXA2 Upstream None 13/141/668 17/212/643 0.00089 0.301 0.922 8/131/438 7/86/263 0.64 0.992 0.0060
rs3759911 ANXA2 Intron None 58/283/
480
84/352/
436
0.0016 0.324 0.295 46/193/245 28/155/155 0.23 0.212 0.0034
rs9926649 DYNC1LI2 Downstream None 7/69/746 0/99/773 0.0017 0.324 0.076 0/48/525 1/31/321 0.48 0.785 0.025
rs2356606 DISC1 Intron None 60/262/
500
32/311/529 0.0023 0.350 0.095 23/209/343 18/117/220 0.47 0.634 0.09
rs6727909 VPS54 Intron None 7/68/747 0/94/778 0.0034 0.460 0.093 1/70/502 0/34/321 0.32 0.343 0.019
rs2306419 ANXA5 Intron None 2/122/698 3/86/783 0.0043 0.524 0.698 4/72/496 4/64/288 0.053 0.834 0.38
rs2171209 VIL2 Intron None 46/210/
566
34/281/
557
0.0048 0.537 0.846 34/185/351 20/130/205 0.43 0.918 0.0096
rs246129 VPS4A Upstream None 106/323/
393
86/404/
382
0.0074 0.692 0.163 49/220/212 30/174/144 0.44 0.025 0.0087
rs12909575 ANXA2 Intron None 42/291/
489
65/349/
458
0.0076 0.692 0.895 37/241/298 29/148/177 0.58 0.803 0.023
rs4658963 DISC1 Intron None 75/329/418 47/344/
481
0.0077 0.692 0.150 39/227/303 22/151/178 0.64 0.176 0.036
rs4930387 SPTBN2 Downstream None 162/445/
215
189/409/
274
0.0099 0.692 0.118 132/312/133 84/181/90 0.62 0.706 0.0049
rs4548 RAB7 Exon Synonym
change
0/96/726 3/75/794 0.020 0.868 0.392 0/62/510 2/42/311 0.20 0.655 0.015
rs10992429 BICD2 3’ UTR 3’ UTR 7/123/688 0/134/737 0.020 0.868 0.014 6/103/461 6/75/272 0.31 0.753 0.38
rs1545539 ANXA2 Intron Regulatory
(predicted)
24/211/587 31/270/571 0.032 0.921 0.895 10/184/387 14/95/249 0.042 0.202 0.10
rs7388 RSN 30 UTR 30 UTR 70/356/
396
59/340/
473
0.035 0.921 0.842 31/214/335 23/140/195 0.55 0.750 0.53
rs776746 CYP3A5 Intron Splicing
defect
8/104/710 1/103/768 0.039 0.921 0.196 2/66/508 0/38/318 0.65 0.287 0.029
rs7167571 ANXA2 Intron None 55/273/
494
40/328/
504
0.049 0.930 0.144 35/205/333 19/121/212 0.81 0.750 0.12
A
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and 361 controls. Since the disease inheritance model is
unknown, we chose SNPs for replication according to the
genotypic test. We did not detect association with any of
the genotyped SNPs in the replication sample (Table 2),
further supporting the lack of association with any of the
SNPs in the discovery sample.
Power calculations
We calculated the power to place an associated variant in
the top 15 SNPs of the first stage of this study, and thus
present as a candidate for our replication study and to
replicate this variant in the second stage (Zaykin and
Zhivotovsky, 2005). We assumed a multiplicative model
with a causal allele frequency of 0.2 (mean observed minor
allele frequency in replication set SNPs) and r2 between the
most associated marker allele and the causal variant of
0.865 (mean r2 in our study). We found that a causal
variant with an odds ratio of 1.47 had 80% power to both
appear in the pool of top 15 SNPs in the first stage and be
replicated in the second stage. We can therefore exclude
well-tagged variants with effect sizes of OR41.47 in
investigated genes as being associated with susceptibility
to ALS, but we also note that due to some failure of
genotyping it is not possible to guarantee that some causal
variants may exist that have high effects sizes but low r2
with any one SNP in our panel.
Discussion
To our knowledge this is the first large systematic pathway-
based study to look at the role of common variation in
susceptibility to sporadic ALS. Many lines of evidence from
analysis of both human disease and animal models have
implicated axonal transport defects in motor neuron death.
Here we show that it is highly unlikely that common
variation in the retrograde axonal transport and vesicle
trafficking genes we assessed has a major effect on disease
susceptibility, at least in the British population, as we
did not find evidence of association in a large cohort of
sporadic ALS patients and controls. Furthermore, we have
excluded variants of moderate effect size by analysing the
replication sample. Similarly, we did not find association
with any of the genes in this study implicated in the
metabolism of xenobiotic substances, with the focus on
pesticide metabolism. A few of the genes—cytoplasmic
dynein 1 heavy chain 1 (DYNC1H1) gene (Shah et al.,
2006), SOD1 (Broom et al., 2004), paraoxonase (PON)
cluster (Saeed et al., 2006; Slowik et al., 2006)—included in
our study have been investigated in small studies before and
an association between ALS and PON genes has been
suggested (Saeed et al., 2006; Slowik et al., 2006). We did
not detect a signal of association with PON1 and PON2
genes in our large dataset; however, we note that we
genotyped a different set of SNPs therefore the data are not
directly comparable.
Given that such mechanisms, especially alterations
in axonal transport, are generally thought to play a major
role in motor neuron disease, the negative findings of our
study are somewhat unexpected. We note, however, that
we cannot exclude the relevance of these pathways to
other neurodegenerative diseases such as spinal muscular
atrophies. The only known familial human mutation in the
dynein–dynactin complex, namely in DCTN1 gene,
results in an atypical form of slowly progressive
lower motor neuron syndrome with major vocal cord
involvement (Puls et al., 2005), and mice mutations in
Dync1h1 give rise to a lower motor neuron phenotype
similar to spinal muscular atrophies rather than ALS. Also,
the human familial mutations in b-III spectrin (SPTBN2),
a dynactin binding protein which is thought to serve as a
link between cargoes and motor proteins, results in
spinocerebellar ataxia type 5 (Ikeda et al., 2006).
Furthermore, we cannot exclude the existence of rare
causal or protective variants which were not assessed by our
association approach. Multiple weakly deleterious variants
can contribute substantially to susceptibility to complex
disease, but they may not reach appreciable frequencies
in populations, especially if they are under weak negative
selection. In this regard we note that genome-wide analysis
of patterns of diversity and divergence of protein-coding
genes showed an excess of genes under weak negative
selection among general vesicle transport and microtubule-
binding motor protein genes (Bustamante et al., 2005), and,
for example four of nine dynein–dynactin complex subunit
coding genes were found to be under weak negative
selection in that study (comparing with 13.5% loci
genome-wide). Furthermore, the dynein–dynactin complex
Table 3 SNPs with nominal P-values50.01 in the discovery sample excluded from replication sample
SNP Gene Location in gene
or distance from
the nearest gene (bp)
Genotype counts
in British patients
Genotype counts
in British controls
P-value
in British
Reason for exclusion
from replication set
rs6904085 Genomic control 317 034 396/329/97 384/421/67 0.00042 Genomic control
rs11862377 DYNC1LI2 Intron 718/94/7 739/131/0 0.0014 r2 0.75 with genotyped
SNP rs9926649
rs363180 DYNC1LI2 Upstream 761/56/5 783/88/0 0.0023 r2 0.81with genotyped
SNP rs9926649
rs206695 Genomic control 500 075 478/310/34 453/361/58 0.0093 Genomic control
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is involved in many essential cellular processes besides its
role in axonal transport and a number of genes, including
all dynein light chain genes are highly conserved among
species (Pfister et al., 2006) and have very few common
polymorphisms in coding sequences. All this indirectly
supports involvement of these genes in complex diseases,
but a multiple rare deleterious variants model may be more
appropriate. Therefore an assessment of all variation in
these genes in ALS and in other forms of motor neuron
disease is needed to fully elucidate their possible role in
motor neuron death.
The general weaknesses of many association studies in
ALS as well as other diseases are inconclusive results,
usually due to inability to discriminate among false positive
findings, limited power to detect variants of moderate effect
size, inconsistent replication results or no attempt at
replication and investigating very small regions of the
genome. We addressed all these issues in our study design,
which therefore allows us to make firm conclusions about
the investigated genes. However, our study had some
limitations too. Selection of candidate genes relied
on existing knowledge of the pathogenesis of ALS.
We did not study all candidate genes; instead we chose a
novel pathway approach and comprehensively screened
genes of the dynein–dynactin complex and associated
pathways, vesicle-trafficking genes and key enzymes
involved in pesticide and other xenobiotics metabolism.
Even so the choice of genes depended on existing biological
knowledge of these pathways and we cannot completely
exclude these pathways as there are certainly more genes
directly or indirectly affecting retrograde axonal transport,
vesicle trafficking and xenobiotic metabolism. In addition,
not all common variants were sampled; however,
the tagging approach let us cover most of the variation.
The large discovery sample size enabled us to look for
variants of moderate effect size and the replication sample
allowed us to discriminate false positive findings. It may be
that by genotyping only a subset of SNPs in the replication
sample we missed variants with lower effect size and
functional variants which were worse represented by
the initially genotyped set of SNPs. Also, some variants
may have population-specific effects, and this is illustrated
by the association between the VEGF gene promoter
polymorphisms and ALS (which is one of the strongest
associations with ALS so far), which has been positive in
three studies (Sweden, Belgium, Birmingham) and negative
in another four (London, Sheffield, The Netherlands, North
America) (Lambrechts et al., 2003; Van Vught et al., 2005;
Brockington et al., 2005; Chen et al., 2006).
There are a few confounding factors which could
have affected the results of our study, and these are
relevant to all disease association studies. For example,
patients were collected and phenotyped in different clinics
over a lengthy period of time and we assume a uniformity
of diagnosis among clinics. Different phenotype data
collected in different clinics makes it difficult to compare
the data and search for genes modifying disease progression
and severity, and there is a degree of variation in the
information available such as ethnicity or family history of
the patient. Sample mix-up diminishes the power of the
study, for example we detected 1–2% sex mismatches among
the samples regardless of which clinic submitted the sample,
indicating that the real magnitude of phenotyping errors is
higher than this. From our experience in other association
studies and anecdotal discussions with other laboratories
carrying out large-scale human disease genetic association
studies (J. Hardy, personal communication), we found that
the number of errors in our study is within the range of that
encountered in many similar scale projects. This points out
the need for stringent quality control for handling samples in
research laboratories and should be taken into account while
creating DNA resources for future studies. However, we note
that by genotyping large numbers of SNPs we were able to
reduce the number of errors by detecting blindly duplicated
samples and related individuals.
We detected a weak signal of differences in population
structure between patient and control samples, even though
most of the controls were collected in the same geographic
areas as the cases. This is not likely to affect results and
conclusions of our study; however, it must be taken into
account planning future studies, especially on the same
patient collections.
A further outcome of this study is that we validated the
use of whole genome amplified DNA on a large scale,
which may significantly ameliorate the use of existing DNA
resources. An important factor limiting genetic studies of
sporadic ALS until now was the lack of large sample
collections providing enough power for association analysis
and the lack of replication and attempts to replicate
published findings. Due to low disease prevalence and
short survival time, it takes many years and much effort to
collect these irreplaceable samples and thus researchers are
reluctant to ‘waste’ DNA to replicate marginally significant
findings with little evidence of true positives. We show
that about a 300-fold increase of DNA amount by whole
genome amplification does not decrease genotyping
quality and the decrease in genotyping efficiency is
negligible (1%).
In conclusion, we did not find evidence for association
between retrograde axonal transport, vesicle trafficking and
pesticide metabolism genes with ALS. However, we looked
only at a small number of ‘good’ candidates, which we
chose from the literature and experimental findings on ALS.
Further large integrated well-designed studies, especially
genome-wide screens, which are independent from prior
knowledge on disease biology, are needed to elucidate
genetic risk factors for sporadic ALS.
Supplementary material
Supplementary data are available at Brain online.
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